Uncategorized
FDA approves Eylea for macular edema following BRVO
The U.S. Food and Drug Administration has approved Eylea for the treatment of macular edema following branch retinal vein occlusion, Regeneron Pharmaceuticals announced in a press release.Eylea (aflibercept) was previously approved for macular edema following central retinal vein occlusion (CRVO).“Retinal vein occlusion (RVO) is a significant cause of vision impairment in the U.S., and this expanded indication across all forms of RVO will provide an important new treatment option for retina specialists and their patients,” George D. Yancopoulos MD, PhD, chief scientific officer of Regeneron and president of Regeneron Laboratories, (Read more...)